[go: up one dir, main page]

BR9917080A - Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica - Google Patents

Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica

Info

Publication number
BR9917080A
BR9917080A BR9917080-9A BR9917080A BR9917080A BR 9917080 A BR9917080 A BR 9917080A BR 9917080 A BR9917080 A BR 9917080A BR 9917080 A BR9917080 A BR 9917080A
Authority
BR
Brazil
Prior art keywords
compound
thromboembolic
dysfunction
prevention
treatment
Prior art date
Application number
BR9917080-9A
Other languages
English (en)
Inventor
John M Fevig
Joseph Cacciola
Charles G Clark
Qi Han
Patrick Yuk San Lam
Donald J P Pinto
James R Pruitt
Mimi L Quan
Karen A Rossi
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9917080(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR9917080A publication Critical patent/BR9917080A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DO COMPOSTO E MéTODO DE TRATAMENTO OU PREVENçãO DE UMA DISFUNçãO TROMBOEMBóLICA". A presente invenção refere-se a heterobicíclicos contendo nitrogênio e seus derivados, ou suas formas de sais farmaceuticamente aceitáveis, que são úteis como inibidores de fator Xa.
BR9917080-9A 1998-12-23 1999-12-17 Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica BR9917080A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11362898P 1998-12-23 1998-12-23
US12763399P 1999-04-02 1999-04-02
PCT/US1999/030316 WO2000039131A1 (en) 1998-12-23 1999-12-17 Nitrogen containing heterobicycles as factor xa inhibitors

Publications (1)

Publication Number Publication Date
BR9917080A true BR9917080A (pt) 2002-03-12

Family

ID=26811284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9917080-9A BR9917080A (pt) 1998-12-23 1999-12-17 Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica

Country Status (26)

Country Link
US (2) US6413980B1 (pt)
EP (1) EP1140941B1 (pt)
JP (1) JP2002533465A (pt)
KR (1) KR100628407B1 (pt)
CN (1) CN100340559C (pt)
AR (1) AR024242A1 (pt)
AT (1) ATE280171T1 (pt)
AU (1) AU759711B2 (pt)
BR (1) BR9917080A (pt)
CA (1) CA2349330C (pt)
DE (1) DE69921358T2 (pt)
DK (1) DK1140941T3 (pt)
EA (1) EA004515B1 (pt)
ES (1) ES2232202T3 (pt)
HK (1) HK1052508B (pt)
HR (1) HRP990396A2 (pt)
IL (2) IL142959A0 (pt)
MX (1) MXPA01006502A (pt)
MY (1) MY138239A (pt)
NO (1) NO319816B1 (pt)
NZ (1) NZ511674A (pt)
PT (1) PT1140941E (pt)
SI (1) SI1140941T1 (pt)
TW (1) TWI225862B (pt)
WO (1) WO2000039131A1 (pt)
ZA (1) ZA200103795B (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506771B2 (en) 2000-06-23 2003-01-14 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl heterobicyclic factor Xa inhibitors
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6960595B2 (en) * 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
US6750225B2 (en) 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
CA2441772A1 (en) * 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
WO2002094197A2 (en) * 2001-05-22 2002-11-28 Bristol-Myers Squibb Company Bicyclic inhibitors of factor xa
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
IL160693A0 (en) * 2001-09-21 2004-08-31 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2003048081A2 (en) * 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
EP1505966A4 (en) * 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
CA2511321A1 (en) * 2002-12-23 2004-07-08 Aventis Pharma Deutschland Gmbh Pyrazole-derivatives as factor xa inhibitors
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US7122557B2 (en) * 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
ZA200508300B (en) * 2003-05-20 2007-03-28 Transtech Pharma Inc RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
CA2539549A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
EP1719409B1 (en) 2004-02-24 2012-07-11 Sumitomo Chemical Company, Limited Insecticide composition
MX2007001953A (es) 2004-08-18 2007-05-09 Astrazeneca Ab Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
JP5184891B2 (ja) 2005-01-07 2013-04-17 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫に関連する用途に用いる化合物
JP2010509392A (ja) * 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
CA2682519A1 (en) 2007-04-18 2008-11-06 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
WO2008133128A1 (ja) 2007-04-18 2008-11-06 Kissei Pharmaceutical Co., Ltd. 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
SI3251660T1 (sl) 2010-02-25 2019-12-31 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
US8884016B2 (en) 2011-06-10 2014-11-11 Dipharma Francis S.R.L. Apixaban preparation process
CN104109165A (zh) * 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CN103992310B (zh) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
CN104395312B (zh) * 2013-06-21 2016-04-27 四川海思科制药有限公司 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用
AR096816A1 (es) 2013-07-08 2016-02-03 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con c-n como agentes para combatir parásitos
WO2015081901A1 (zh) * 2013-12-06 2015-06-11 四川海思科制药有限公司 取代的4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物及应用
WO2015162551A1 (en) 2014-04-21 2015-10-29 Mylan Laboratories Ltd Process for the preparation of apixaban
CN105085515B (zh) * 2014-05-22 2019-02-01 华北制药股份有限公司 作为凝血因子Xa抑制剂的酰肼类化合物
EP3147283B1 (en) * 2014-05-22 2022-08-17 North China Pharmaceutical Company., Ltd. Hydrazine compound as blood coagulation factor xa inhibitor
CA2959987C (en) 2014-09-02 2023-05-09 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Pyrazolo[3,4-c]pyridine compounds and their anti-thrombosis effect
WO2016035007A2 (en) 2014-09-05 2016-03-10 Unichem Laboratories Limited An improved process for the preparation of apixaban and intermediates thereof
CN104311575B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 含有稠环的吡唑并哌啶酮类化合物及其组合物及用途
CN104311574B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 含有噻唑的吡唑并哌啶酮类化合物及其组合物及用途
CN104311556B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有环氧烷基取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311557B (zh) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 含有二酮取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104277037B (zh) * 2014-09-19 2015-12-09 广东东阳光药业有限公司 含有螺环的吡唑并哌啶酮类化合物及其组合物及用途
CN104311555B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
CN104530029B (zh) * 2014-12-09 2017-04-12 广东东阳光药业有限公司 作为Xa因子抑制剂的杂环化合物及其使用方法和用途
CN104513239B (zh) * 2014-12-10 2017-08-22 沈阳药科大学 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
US10077263B2 (en) 2016-04-29 2018-09-18 Optimus Drugs Private Limited Process for the preparation of Apixaban
WO2018150286A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Pharmaceutical composition of apixaban
CN107235986B (zh) * 2017-05-27 2019-04-12 华南师范大学 一种合成氮氧杂桥联唑啉化合物的方法
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
KR102672512B1 (ko) 2018-09-12 2024-06-10 노파르티스 아게 항바이러스 피리도피라진디온 화합물
KR102128509B1 (ko) * 2018-12-19 2020-07-01 한국과학기술연구원 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds
HRP20250950T1 (hr) 2019-11-13 2025-10-24 Unison Pharmaceuticals Pvt. Ltd. Oralno raspadajući farmaceutski pripravci apiksabana
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
CN113956248B (zh) * 2021-11-12 2023-07-04 贵州中医药大学 一种具有抗炎作用的化合物衍生物及其制备方法和应用
CA3235765A1 (en) * 2021-11-12 2023-05-19 Jianping Wu Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2025067258A1 (zh) * 2023-09-25 2025-04-03 上海济煜医药科技有限公司 哒嗪酮类化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
US3423414A (en) * 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3939161A (en) * 1973-10-29 1976-02-17 Abbott Laboratories 1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones
JPS5721388A (en) * 1980-07-11 1982-02-04 Nippon Nohyaku Co Ltd Condensed pyrazole derivative
JPS63145282A (ja) * 1986-12-08 1988-06-17 Taiyo Yakuhin Kogyo Kk ピリダジン誘導体
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
ATE236163T1 (de) * 1991-08-07 2003-04-15 Suntory Ltd Pyrroloazepinverbindungen
WO1994020460A1 (en) 1993-03-11 1994-09-15 Smithkline Beecham Corporation Chemical compounds
WO1995001980A1 (en) * 1993-07-06 1995-01-19 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines
NZ292991A (en) * 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AU1345697A (en) * 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
DE69716810T2 (de) * 1996-05-15 2003-02-27 Pfizer Inc., New York 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
FR2750862B1 (fr) * 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
SK179899A3 (en) * 1997-07-03 2001-12-03 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
EP1064270B1 (en) * 1998-03-27 2004-10-06 Bristol-Myers Squibb Pharma Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
DE19845153A1 (de) 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
DE19900471A1 (de) 1999-01-08 2000-07-13 Merck Patent Gmbh Imidazo[4,5c]-pyridin-4-on-derivate
HUP0203954A2 (hu) 1999-09-17 2003-03-28 Millennium Pharmaceuticals, Inc. Xa faktor inhibitorok

Also Published As

Publication number Publication date
SI1140941T1 (en) 2005-04-30
CA2349330A1 (en) 2000-07-06
DK1140941T3 (da) 2005-02-14
MY138239A (en) 2009-05-29
EP1140941A1 (en) 2001-10-10
HK1052508A1 (zh) 2003-09-19
NO319816B1 (no) 2005-09-19
NZ511674A (en) 2003-11-28
NO20013072D0 (no) 2001-06-20
EA200100688A1 (ru) 2001-12-24
HK1052508B (zh) 2008-08-01
PT1140941E (pt) 2005-02-28
IL142959A (en) 2010-05-31
CN100340559C (zh) 2007-10-03
AR024242A1 (es) 2002-09-25
KR20010092754A (ko) 2001-10-26
ES2232202T3 (es) 2005-05-16
DE69921358D1 (de) 2004-11-25
IL142959A0 (en) 2002-04-21
US6673810B2 (en) 2004-01-06
HRP990396A2 (en) 2000-08-31
WO2000039131A1 (en) 2000-07-06
US20030004167A1 (en) 2003-01-02
CA2349330C (en) 2009-09-29
KR100628407B1 (ko) 2006-09-26
AU2371700A (en) 2000-07-31
CN1391575A (zh) 2003-01-15
TWI225862B (en) 2005-01-01
JP2002533465A (ja) 2002-10-08
ZA200103795B (en) 2002-08-12
DE69921358T2 (de) 2006-03-09
US6413980B1 (en) 2002-07-02
NO20013072L (no) 2001-06-20
AU759711B2 (en) 2003-04-17
EA004515B1 (ru) 2004-04-29
MXPA01006502A (es) 2002-04-08
ATE280171T1 (de) 2004-11-15
EP1140941B1 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR9813835A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
BR9810137A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromoboembólica
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
DK0696280T3 (da) Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister
ECSP055525A (es) Inhibidores de cinasas de tirosina
BR9810151A (pt) Composto, composição farmacêutica e método para tratamento ou prevenção de uma desordem tromoboembólica
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
BRPI0415437A (pt) composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
BR0309498A (pt) Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças que são relacionadas com o ras, e, uso de compostos
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
AP9701041A0 (en) Pyridylpyrrole compounds.
DE60324544D1 (de) Muskarin antagonisten
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
BR0014381A (pt) Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
BR9908702A (pt) Composto, processos para inibir sìntese de óxido nìtrico em um paciente, para inibir seletivamente sìntese de óxido nìtrico produzido pela no sintase indutìvel no óxido nìtrico produzido pelas formas constitutivas de no sintase em um paciente e para diminuir nìveis de óxido nìtrico em um paciente, e, composição farmacêutica
GB0222514D0 (en) Organic compounds
NO984470L (no) Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase
SE0101932D0 (sv) Pharmaceutical combinations
BR0213154A (pt) Compostos de glicopeptìdeo - cefalosporina de ligação reticulada, composições farmacêuticas de tais compostos, método de fabricação dos mesmos e seus usos

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements